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There is a significant current need to elucidate the molecular mechanisms of the 
side-effects caused by widely-used pharmaceuticals. Examples include the acute 
nephrotoxicity and irreversible ototoxicity promoted by the cationic drugs gentamicin and 
cisplatin. Gentamicin is an aminoglycoside antibiotic used for the prevention and 
treatment of life-threatening gram-negative bacterial infections, such as tuberculosis and 
meningitis. Cisplatin is used to treat a broad spectrum of cancers including head and neck, 
ovarian, cervical, stomach, bladder, sarcoma, lymphoma, testicular cancer and others.  
The objective of this study is to design and synthesize rhodamine derivatives that 
can be used for the construction of geometrically well-defined cationic drug conjugates. 
The long-term goal is to use the conjugates as tools to aid in elucidating the properties 
and identities of ion channels involved in the uptake of cationic pharmaceuticals into 
kidney and cochlear hair cells. This will shed light on the origin and potential prevention 
of unwanted side effects such as nephrotoxicity and ototoxicity associated with specific 
cationic drugs.  
A series of extended rhodamine analogs with reactive groups for biomolecule 
conjugation has been synthesized. These fluorophores show similar spectral properties to 
their prototype, Texas Red succinimidyl ester (TR-SE). However, they contain rigid 
linkers between the fluorophore and amine-reactive moiety. The resultant gentamicin 
conjugates of these materials are rigidified enabling one to assess channel pore 
dimensions without the confounding issue of conjugate folding. Preliminary cell studies 
are promising, as one observes reduced gentamicin uptake in both kidney and sensory 
ii 
 
hair cell upon systematically increasing the dimension of the fluorophore. This work has 
enabled us to tentatively assign the maximum dilated MET channel pore size as between 
1.44 nm to 1.56 nm. However, this preliminary finding, though encouraging, needs 
further validation via ongoing studies with larger diameter fluorophore conjugates, 
A cisplatin-Texas Red conjugate has also been synthesized to enable studies of 
cellular uptake mechanisms. This conjugate preserves not only the spectral properties of 
Texas Red after conjugation, but also the cytotoxicity of cisplatin. This has been 
validated in zebrafish. The series of rhodamine probes that have been conjugated to 
gentamicin should be similarly useful for cisplatin studies. These studies are planned. 
Additional future work includes the synthesis of semi-flexible (glycol) and flexible 
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CHAPTER 1      INTRODUCTION 
Most medications, regardless of whether they are of the over-the-counter or 
prescription variety, exhibit a certain level of undesirable and sometimes life-threatening 
side-effects. Two examples of widely-prescribed drugs that cause profound side effects in 
extremely high percentages of the patients using them are gentamicin and cisplatin. 
Although they possess very dissimilar structures and treat different diseases, each causes 
acute renal dysfunction and irreversible hearing loss.  
 
1.1 Gentamicin 
Gentamicin, a major aminoglycoside antibiotic naturally produced by 
Micromonospora, is composed of three major isomeric components C1, C1a and C2, as 







 and in the prevention of sepsis infections in 
burn patients
4
 and premature babies.
5
 However, irreversible ototoxicity and acute 
nephrotoxicity are serious side effects in patients. Every year > 600,000 new-born babies 
receive gentamicin for a diagnosis of potential sepsis.
5
 Over 10% of all patients that 
receive aminoglycoside antibiotics suffer from drug-induced hearing loss.
6
 The lifetime 
opportunity cost for hearing impairment was estimated at $1 million in 2000 for each pre-
lingual deaf child.
7
 Approximately 14% of all patients receiving gentamicin treatment 
also experience acute loss of kidney function.
6
 Despite these risks, gentamicin is a 







Figure 1.1 Gentamicin isomers  
 
1.2 Bactericidal mechanism of gentamicin 
Aminoglycosides (AGs) such as gentamicin irreversibly bind to the 30s subunit of 
the bacterial ribosome responsible for protein synthesis. Binding triggers a cascade of 
events leading to cell death, beginning with altered protein biosynthesis, due to the 
misincorporation of amino acids into elongating peptides. The resulting proteins are often 
misfolded and dysfunctional. When incorporated into the cytoplasmic membrane, 
misfolded proteins enhance the permeability of the cell membrane, thereby further 
enhancing gentamicin uptake and toxicity. Mistranslated bacterial membrane proteins 
additionally disrupt the signaling mechanism that counteracts the cytotoxicity of AGs as 







Figure 1.2 The mechanism of aminoglycoside binding to bacteria and the induction of 
cell death. Aminoglycosides bind to the 30s subunit of the ribosome causing misfolded 
proteins to be synthesized. Misfolded membrane proteins lead to enhanced drug uptake 




1.3 Trafficking routes of gentamicin into the cochlea associated with deafness  
Many studies have focused on the intracellular mechanisms of unwanted side-
effects of AGs in the kidney and cochlear sensory hair cells in the inner ear. However, the 
precise route of drug trafficking from the vasculature across the blood-labyrinth barrier 
and into sensory hair cells in the inner ear is still not completely understood. 
Aminoglycosides could enter hair cells via various mechanisms (Figure 1.3, route 1) 
including apical endocytosis
10-12
 and via ion channels such as the mechanoelectrical 
(MET) transduction channel
13 on the apical surface of the cochlear hair cells. This 
indicates that the most viable route for systemically-administered AGs in vivo is believed 
to take place via passage from the strial capillaries into the endolymph (trans-strial 
trafficking mechanism) prior to entering hair cells through MET channels, as shown in 
Figure 1.3, route 2.
13,14
 There are potential alternative trafficking pathways that AGs 
could take prior to entering hair cells, such as via capillaries in the spiral ligament of the 
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lateral wall into the perilymph of the scala tympani and across the baso-lateral membrane 
of hair cells. (Figure 1.3, route 3 and 4). 
 
 
Figure 1.3 Potential trafficking routes of gentamicin entering cochlea.  
(Route 1) Aminoglycosides are known to enter hair cells via apical endocytosis or 
permeation of the MET channels on the apical surface of hair cells. (Route 2) AGs could 
enter the endolymph via a trans-strial trafficking route from stria capillaries to marginal 
cells, or (Route 3) by traversing the blood labyrinth barrier into perilymph and then 
(Route 4) into hair cells across their baso-lateral membranes (diagram not to scale). This 






Cisplatin (cis-diamminedichloroplatinum[II]) is a platinum-containing anti-cancer 
drug, whose bioactivity was discovered by Rosenberg et al. in 1965.
16
 Since then, 
cisplatin has become a cornerstone of antineoplastic chemotherapy to treat many types of 
cancer, including ovarian, cervical, stomach, bladder, head and neck.
17-19
 Cisplatin is 





 Every year more than one million patients receive cisplatin or its 
derivatives in North America and Europe. Unfortunately, the clinical use of cisplatin is 
limited by acquired drug resistance and severe dose-dependent side effects, such as 
ototoxicity and nephrotoxicity (similar to gentamicin, above). Clinical studies show that 
> 60% of patients taking multiple doses of cisplatin will develop permanent hearing 
loss
21,22
 and acute renal dysfunction.
23
 Drug-induced hearing loss can severely affect an 
individual’s quality of life. Consequences can include social isolation, depression and 
loss of income. Children can exhibit delayed development of communication and 
learning skills, and have a relatively challenging time developing social interactions.
21,22
 
Therefore, an understanding of the fundamental biological mechanisms that lead to 
cisplatin-induced ototoxicity and nephrotoxicity can have a profound impact on patients’ 
lives, especially if it can inform the development of less harmful therapeutic options, or 
the development of otoprotective strategies.   
 
 
Figure 1.4 Cisplatin 
 
1.5 Mechanism of action of Cisplatin 
During chemotherapy, cisplatin binds to DNA, disrupting genetic function and 
selectively killing rapidly proliferating cells such as cancer cells. The underlying 
mechanism involves ligand exchange within the cells of cisplatin’s chlorides for H2O, in 





 position of purines on DNA, forming cisplatin-DNA adducts, distorting the 
helical structure of DNA (Figure 1.5).
24
 Cells identify this as damaged DNA, activating 




Figure 1.5 Aquation of cisplatin and insertion into DNA helical structure. 
 
Oxidative stress is thought to be another major mechanism of cisplatin-induced 
ototoxicity and nephrotoxicity.
26
 Once cisplatin enters cells, the charged aquated-
platinum complex rapidly interacts with thiol-containing antioxidant molecules such as 
glutathione and methionine.
27
 The depletion of antioxidants leads to cytotoxic levels of 
reactive oxygen species (ROS) and lipid peroxidation product accumulation in cells. 
Other mechanisms whereby cisplatin promotes elevated levels of ROS are via the 
respiratory chain
28




1.6 Trafficking routes of cisplatin into hair cells 
As shown in Figure 1.6, cisplatin has an uptake route into cochlear hair cells 
analogous to that described above for gentamicin, entering the endolymph via a trans-
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strial trafficking route from stria vascularis (route 2). To date, several studies have shown 
that one or several candidate membrane transporters potentially play an important role in 
cisplatin uptake and efflux pathways to induce cytotoxicity, and cochleotoxicity (hearing 
loss). These include the copper transporters (Ctr1 and ATP7A) and the organic cation 
transporter (Oct2).
30-32
 Ciarimboli et al.
33
 using a Oct2 inhibitor, cimetidine, and More et 
al.
34
 using the competitive inhibitor, CuSO4, have observed protection from cisplatin-
inducing hearing loss in vivo, as further evidence of the involvement of Oct2 and Ctr1 in 
cisplatin uptake into healthy cells. However, results reported by Thomas et al. using a 
rhodamine-cisplatin conjugate showed that MET channel function is required for 
cisplatin-induced hair cell cytotoxicity, while Crt1 and Oct2 are not involved in the 
cisplatin uptake mechanism.
35
 In other words, there is a significant current need to clarify 
the mechanism of cisplatin entry into cochlear hair cells.  
 
 
Figure 1.6 The trans-strial trafficking pathway for cisplatin from stria vascularis.  
The candidate cisplatin transporters are located on the strial capillaries including Oct2, 
Ctr1 and ATP7A (M, marginal cell; I, intermediate cell; B, basal cell; E, endothelial cell) 




CHAPTER 2      DESIGN, SYNTHESIS AND CHARACTERIZATION OF 
CONJUGATABLE RHODAMINE ANALOGS  
2.1 Introduction  
Fluorescent probes are widely used for the detection of specific biomolecular 
pathways and cellular events. The objective of this study is to synthesize rigid, 
geometrically well-defined rhodamine derivatives to serve as the optical components of 
cationic drug-fluorophore conjugates. The long-term goal is to use these drug-
fluorophore conjugates to determine the dimensions of ion channels involved in the 
cellular uptake of pharmaceuticals such as gentamicin. This is significant because new 
information on cellular trafficking can shed light on the mechanism, and potential 
prevention of side effects such as ototoxicity and nephrotoxicity.  
Fluorescein, BODIPY and acridine dyes (Figure 2.1) have been conjugated to 





 and for use in fluorescent immunoassays.
39
 The fluorescent conjugate of 
gentamicin and Texas Red (GTTR, 2.1) has been of great utility in the study of non-
endocytotic aminoglycoside uptake and intracellular localization (Figure 2.2).
40,41
 Texas 
Red succinimidyl ester (TR-SE, 2.2) is the fluorophore used for gentamicin conjugation 








Figure 2.1 Aminoglycosides labeling reagents and structures 
 
 
Figure 2.2 Isomers of Gentamicin-Texas Red conjugate (GTTR, 2.1) and Texas Red 
succinimidyl ester (TR-SE, 2.2)  
 
2.2 Molecular shape modifications of rhodamine analogs  
GTTR in vivo studies have been mainly performed in fixed cells since live cells 
quench GTTR fluorescence.
40
 This fluorescence quenching has been attributed in part to 
the interactions between gentamicin and phospholipids. It has been reported that cationic 
10 
 
aminoglycosides have high affinity for the anionic phospholipid phosphatidylinositol 4, 
5-bisphosphate (PIP2, Figure 2.3).
45,46
 GTTR fluorescence quenching in cells was 
determined by Myrdal et al. Results from these studies indicate that gentamicin binding 
to PIP2 and similar phospholipids (PLs) is likely responsible for quenching GTTR 
fluorescence in live cells and that this quenching can be unmasked by delipidating cells 




Figure 2.3 Phosphatidylinositol 4, 5-bisphosphate (PIP2) 
 
Molecular modeling was used to guide the design of new fluorophores for 
conjugation to gentamicin to allow the study of gentamicin cellular uptake trafficking in 
live and fixed cells. Simulations showed that the current GTTR conjugate, 2.1 used in 
preliminary studies, has a sulfonated-flexible linker between the gentamicin and Texas 
Red moieties that promotes folding of the structure and interactions between the 






Figure 2.4 Molecular simulations of 2.1, showing that the flexible linker promotes the 
interaction between fluorophore and gentamicin 
 
 
Also, the energy-minimized structure of stretched conformer of GTTR (Figure 
2.5A) has a maximal cross-sectional diameter of 1.35 nm, and can pass through cation-







 likely through pore dilation.
49
 MET channels have a minimum pore size of 
1.25 nm
50
; TRPV1 channels have an open pore size of ~1 nm
51,52
 that increases following 
agonist-induced pore dilation,
49,53
 TRPV4 channels have a larger pore diameter
54
 that 
allows organic cation permeation upon agonist-induced activation.
55
 
Because of the correlation between the molecular simulations and the results of 
preliminary studies using the current gentamicin conjugate 2.1, it is hypothesized that 
rigidifying the linker will avoid potential intramolecular interactions between the 
fluorophore and gentamicin, and thereby inhibit fluorescence quenching. In addition, the 
12 
 
incorporation of a rigid liker will prevent conjugate bending as a means of passing 
through ion channels, and thus act as a molecular ruler of channel pore diameter.  
In order to test the hypothesis that systematic molecular shape modifications of 
the fluorophore and linker can afford control over hair cell and kidney cell gentamicin 
uptake and toxicity, a series of inflexible rhodamine analogs were designed and 
synthesized. Molecular simulations show that a biaryl linker (2.3, Figure 2.5B) meets the 
requirement to prevent intramolecular interactions between the fluorophore and the 
gentamicin moieties, and possesses a cross-sectional diameter of 1.44 nm. The cross-
sectional diameter of the final conjugate can be increased to 1.56 nm by adding four 
methyl groups to the fluorophore scaffold (2.4, Figure 2.5C). Additional [1,2]-butano 
fused rings on the fluorophore framework furnishes a conjugate with a cross-sectional 
diameter of 1.85 nm (2.5, Figure 2.5D). The design of these rigid probes allow them to be 
used as molecular rulers, to aid us in determining the maximum diameter of dilated AG-





Figure 2.5 Molecular simulations of rhodamine analogs conjugated with gentamicin. 
(A) Flexible GTTR, yellow atoms represent sulfur atoms. (B) Sulfur atoms are replaced 
by para-phenyl rings, to give inflexible conjugates. (C, D) Adding methyl groups or 
[1,2]-butano fused rings increases the diameter of the conjugate. 
 
 
2.3 Synthetic strategies of rhodamine analogs 
Figure 2.6 shows the three fluorophore structures that were proposed from the 
simulations. The figure shows the inflexible biaryl linkers of each, as well as the 




Figure 2.6 Designed fluorophores for conjugation to gentamicin 
 
2.3.1 Synthesis of inflexible Texas Red, 2.6 
 
Figure 2.7 Proposed Inflexible Texas-Red, 2.6 
 
Based on the molecular simulation results, inflexible Texas Red analog 2.6 
possesses a diameter of 1.44 nm. As shown in scheme 2.1, compound 2.6 was 
synthesized in four steps with an overall yield of 13%. The initial step involves the 
condensation of 8-hydroxyjulolidine 2.9 and 4-bromobenzaldehyde 2.10 under 
microwave conditions followed by addition of p-chloranil as an oxidant to give bromo-
substituted rhodamine 2.11 in 47%.
56
 Suzuki-coupling of 2.11 with 4-(N-Boc-amino) 
phenylboronic acid was carried out in the presence of K2CO3 in MeOH, heated at reflux 
15 
 
overnight to afford Boc-protected amino biphenyl Texas-Red 2.12 in 45%. Removal of 
the Boc group using trifluoroacetic acid gave the free amine 2.13,
57
 which was reacted 





Scheme 2.1 Synthesis of inflexible Texas Red, 2.6 
 
2.3.1 Synthesis of inflexible rhodamine, 2.7 
 
Figure 2.8 Proposed extended inflexible rhodamine, 2.7 
16 
 
Rhodamine 2.7 possesses four methyl groups on the fluorophore scaffold 
resulting in a diameter of 1.56 nm. As shown in scheme 2.2, the required hydroxyl-
quinoline 2.17 was synthesized using a modified procedure as described by Belov et al.
59
 
Trimethyl-dihydroquinoline amine 2.15 was obtained in 80% yield by condensation of m-
anisidine with acetone at rt for 24 h using ytterbium triflate as the catalyst. Further 
alkylation of 2.15 with methyl iodide in the presence of cesium carbonate gave the 
tetramethyl-dihydroquinoline 2.16 in 89% yield. Nucleophilic dealkylation of 
intermediate 2.16 with 48% aq. HBr in acetic acid gave the corresponding hydroxyl-
quinoline 2.17 in 54% yield. 
 
Scheme 2.2 Synthesis of hydroxyl-quinoline precursor 2.17 
 
As shown in scheme 2.3, initial attempts (Route 1) to prepare the succinimidyl 
activated ester 2.7 involved the synthesis of the bromo-substituted rhodamine 2.18 
published by Jiao et al.
56
 followed by a Suzuki coupling reaction with (4-
(methoxycarbonyl)phenyl)boronic acid.
60
 After extensive optimization, the Suzuki 
coupling reaction of bromo-substituted rhodamine with boronic acid gave precursor 2.19; 
however, the reaction was sluggish (it required five days) and gave rise to mixtures hard 
to separate. Therefore, an alternative approach (Route 2) involving the direct 
condensation of the hydroxyl-quinoline 2.17 and methyl 4-(4-formylphenyl)benzoate 
2.20 was evaluated. The methyl ester precursor 2.19 was obtained in 67 % yield by 
17 
 
condensation of hydroxy-quinoline 2.17 and methyl 4-(4-formylphenyl)benzoate 2.20 
under microwave conditions in the absence of solvent at 150 
o
C followed by oxidation 
with p-chloranil. The hydrolysis of methyl ester intermediate 2.19 was conducted under 
basic conditions using LiOH in a mixture of MeOH:THF:H2O (5:3:1) to give compound 
2.21 in 78%. The activated succinimidyl ester 2.7 was achieved in 84% yield using 
EDAC as the coupling reagent. The target fluorophore 2.7 was synthesized in six steps 
with an overall yield of 17%. 
 
Scheme 2.3 Synthesis of compound 2.7 
18 
 
2.3.2 Synthesis of inflexible rhodamine, 2.8 
 
Figure 2.9 Designed extended-inflexible fluorophore with additional [1,2]-butano fused 
rings 2.8 and 2.22 
 
Two extended inflexible Texas Red with additional [1,2]-butano fused rings on 
the fluorophore scaffold are shown in Figure 2.9. While compound 2.8 fulfills the 
proposed architectural goals, compound 2.22 with its additional cyano groups is also of 
interest. The cyano substituents may positively influence the spectra properties such as 
enhancing quantum yield. Retrosynthetic analysis of compound 2.22 (Figure 2.10) was 
envisioned as including the condensation of cyano-hydroacridinol 2.23 and commercial 
available methyl 4-(4-formylphenyl)benzoate 2.20, using similar reaction conditions as 
described above for the synthesis of compound 2.19. Therefore, in order to accomplish 
the goal to synthesize the cyano-hydroacridinol 2.23, a divergent route was pictured as 
incorporating the ring opening of aziridine 2.27 by nucleophilic substitution with 
bromophenyl acetonitrile 2.24 followed by Pd-catalyzed intramolecular C-N 
cycloaddition.
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 Bromophenyl acetonitrile 2.24 can be synthesized from aldehyde 2.26 
via reduction and bromination followed by substitution with cyanide. Aziridine 2.27 can 
19 
 
be synthesized via a Mitsunobu reaction using ring-opened expoxide 2.28. The overall 
synthesis of cyano-hydroacridinol 2.23 is shown in Scheme 2.4.   
 
 
Figure 2.10  Retrosynthetic strategy for synthesis of compound 2.22 
 
 
As shown in Scheme 2.4, benzyl bromide 2.25 was synthesized in two steps by 
using  procedures as described previously by Bower et al.
62
 Reduction of aldehyde 2.26 
afforded alcohol 2.29 in near quantitative yield with NaBH4. Alcohol 2.29 was 
brominated with PBr3 at 0 
o
C to afford benzyl bromide 2.25 in 95% yield. Cyanide 2.24 
was added via an SN2 reaction in 83% yield.
63
 Aziridine 2.27 was prepared in two steps 
as described by Shen et al.
64
 -amino alcohol 2.30 was synthesized via nucleophilic 
addition of methyl amine to epoxide 2.28 in 100% yield. However, the ring-closure of 
amino alcohol under Mitsunobu reaction conditions provided only a trace amount of 
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aziridine 2.27. It proved hard to purify and obtain in good yield, as multiple components 
were observed in the crude product mixture.  
 
  Scheme 2.4 Synthesis of precursor 2.24 and 2.27 
 
Retrosynthetic analysis (Figure 2.11) of decahydroquinoline 2.8 was envisioned 
as occurring via the condensation of hydroacridinol 2.32 and the commercial available 
2.20, using similar reaction conditions as described above for the synthesis of compound 
2.19. Decarboxylative cycloaddition of isatoic anhydride 2.35 to cyclohexene 2.36 would 
form acridione 2.34. Reduction of the ketone and dealkylation of the methoxy group 
would furnish desired intermediate 2.32. 
 
 
Figure 2.11 Retrosynthetic strategy for the synthesis of compound 2.8 
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Isatoic anhydride 2.39 was synthesized using a modified version of a procedure 
described by Acker et al.
65
 This approach involved two additional eliminations from 
anthranilic acid 2.37 reacting with triphosgene 2.38 under reflux condition to give isatoic 
anhydride 2.39  in 95% yield (Scheme 2.5). Alkylation of isatoic anhydride 2.39 with 
methyl iodide gave the corresponding N-methyl isatoic anhydride 2.35 in 93% yield.
66
 In 
order to obtain intermediate 2.34, nickel-catalyzed decarboxylative cycloaddition of 
isatoic anhydride 2.35 with cyclohexene 2.36 was investigated using the procedure 
described by Sun et al.
67
 Zinc was prepared and activated using a protocol described by 
Vogel et al,
68
 or commercially available Rieke Zinc. However, all attempts to produce the 
cycloaddition product 2.34 using either freshly prepared activated Zn or commercially 
available Rieke Zinc were unsuccessful. ESI MS analysis showed that a mass 
corresponding to an intermediate of the target compound 2.34 was present in the crude 
mixture. However the mass corresponding to 2.34 was not found and numerous TLC 
spots were observed when analyzing the product mixture. 
 
 




After several failed attempts to synthesize hydroacridinol 2.32, an alternative 
approach, involving no previously-reported intermediates, was designed as shown in 
Scheme 2.6. The retrosynthetic analysis is shown in Figure 2.12. It is envisioned a 
Friedel-Crafts acylation of 2.40 followed by reduction and dealkylation to afford target 
2.32. Forging the C-C bond through intramolecular from N-phenylcarboxylic acid 2.40 to 
form hydroacridinone 2.34. N-phenylcarboxylic acid 2.40 would be derived from 
reductive amination via the reaction of aniline 2.41 and -ketoester 2.42. 
 
Figure 2.12 An alternative retrosynthetic strategy for attaining compound 2.32 
 
As shown in Scheme 2.6, the reductive amination of aniline 2.41 and -ketoester 
2.42 with NaBH(OAc)3 affords product 2.43 in 69% yield.
69
 Alkylation of 2.43 with MeI 
gives the corresponding N-methylated product 2.44 in 80% yield. Compound 2.44 was 
hydrolyzed under basic conditions at rt to afford 2.40 in 99%. After reaction optimization, 
the cyclization of hydroacridinone 2.40 in polyphosphoric acid (PPA) led to 
hydroacridinone 2.34 in a low yield of 16% via intramolecular Friedel-Crafts acylation.
70
 
Reduction of hydroacridinone 2.34 using LiAlH4 under reflux conditions gave the 
corresponding acridine 2.33 in 90 %.
71
 The target intermediate hydroacridinol 2.32 was 
successfully obtained in 99% yield by nucleophilic dealkylation of the methoxy ether 
using 48% aq. HBr. The target compound 2.8 was synthesized in three steps using a 
similar strategy as described above for extended Texas Red 2.7, which involves the 
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condensation of hydroacridinol 2.32 and methyl 4-(4-formylphenyl)benzoate 2.20 in 49% 
yield, and basic hydrolysis of the methyl ester 2.45 gave 2.46 in 99% yield. The activated 
succinimidyl ester 2.8 was obtained in 85% yield using EDAC as the coupling reagent. 
 
 
Scheme 2.6 Synthesis of compound 2.8 
 
2.4 Spectral properties 
In order to determine that the new fluorophores have the similar spectral 
properties as compared to the parent probe TR-SE (2.2), the absorbance and fluorescence 
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spectra of 1.25 M solution of compound 2.2, 2.6, 2.7 and 2.8 were evaluated in organic 
solvent (MeOH) and buffer (PBS:DMSO 9:1). 
The absorption spectrum of 2.6 has a similar maximum absoprtion as compared to 
2.2, while compounds 2.7 and 2.8 show a 30% reduction in absorption (Figure 2.13). The 
fluorescence properties of 2.2, 2.6, 2.7 and 2.8 in MeOH and buffer are summarized in 
Table 2.1. As shown in Figures 2.14 and 2.15, compound 2.6 has only a 5 nm Stoke’s 
shift change as compared to that of 2.2.  
Compounds 2.7 and 2.8 have small wavelength shifts in their fluorescence spectra 
in comparison to 2.2. Compound 2.7 contains an extra double bond, which extends the 
conjugation leading to a slight red shift (5 nm in excitation spectra and 15 nm in emission 
spectra). Compound 2.8 has somewhat less rigid aliphatic rings and shows a blue shift 
(25 nm in excitation spectra and 10 nm in emission spectra) compared to 2.2. 
The relative fluorescence quantum yields () of 2.6, 2.7 and 2.8 were calculated 
by using TR-SE 2.2 as the reference standard (Table 2.1). A reduction of 30 % in 
quantum yield is observed for compound 2.6 and a reduction of 17 % in quantum yield is 
observed for the compound 2.7. However, compound 2.8 has 10 % enhancement in 
quantum yield as compare to TR-SE 2.2. 
TR-SE, (2.2) in both MeOH and 90 % PBS:DMSO solvents has similar 
absorbance and fluorescence intensities. A higher absorbance/fluorescence intensity is 
observed for 2.6, 2.7 and 2.8 in organic solvent systems, compared to PBS/DMSO. This 
is attributed to the aggregation and - stacking effects that are mitigated in 2.2 due to 





Figure 2.13 Absorption spectra of 2.2, 2.6, 2.7 and 2.8. Probe concentration: 1.25 M. 
Solvent: MeOH 
 
Table 2.1 Comparison of the fluorescence properties of compounds 2.2, 2.6, 2.7 and 2.8 
Compound MeOH PBS:DMSO 9:1 Relative  
Quantum yield 
 ex/em (nm) ex/em (nm) () 
2.2 580/600 590/610 1 
2.6 575/600 580/600 0.71 
2.7 590/615 590/620 0.83 






























Figure 2.14 Normalized fluorescence excitation spectra of 2.2, 2.6, 2.7 and 2.8. Probe 




Figure 2.15 Normalized fluorescence emission spectra of 2.2, 2.6, 2.7 and 2.8. Probe 









































































Figure 2.16 Absorption spectra of 2.2, 2.6, 2.7 and 2.8. Probe concentration: 1.25 M. 




Figure 2.17 Normalized fluorescence excitation spectra of 2.2, 2.6, 2.7 and 2.8. Probe 
































































Figure 2.18 Normalized fluorescence emission spectra of 2.2, 2.6, 2.7 and 2.8. Probe 
concentration: 1.25 M. Solvent: PBS:DMSO 9:1 
 
 
2.5 Experimental section 
Material and Methods 





C-NMR and were acquired on an ARX-400 Avance Bruker spectrometer. 
Chemical shifts (δ) are given in ppm relative to TMS. Mass spectra were obtained at the 
PSU Bioanalytical Mass Spectrometry Facility on a ThermoElectron LTQ-Orbitrap 
Discovery high resolution mass spectrometer coupled to an Accela HPLC system. 
Microwave synthetic procedures were performed in an Initiator™ microwave synthesizer 
(Biotage). Simulations were performed on a Dell precision™ 490 work station loaded 
with CentOS 6.6 64-bit operating system using the molecular dynamics routines within 





































carried out on a Cary Eclipse
TM
 fluorescence spectrophotometer (Agilent Technologies). 
Absorption spectra were acquired with a Cary Eclipse
TM
 50 Bio UV-Vis 
spectrophotometer. 
Synthesis of compound 2.11.  In a 20 mL microwave tube, 8-hydroxyjulolidine 
(380 mg, 2 mmol) and 4-bromobenzaldehyde (185 mg, 1 mmol) were dissolved in 7.5 
mL of methanesulfonic acid. A magnetic stirring bar was introduced and the tube was 
sealed and irradiated in the microwave reactor keeping the temperature at 150 ºC with 
stirring for 5 min. The mixture was allowed to cool to rt, and the tube opened. 
Tetrachloro-1,4-benzoquinone (369 mg, 1.5 mmol) was added to the solution, and stirred 
for 15 min. The dark blue mixture was neutralized to pH 7 with 10 M KOH. The solution 
was poured into H2O and extracted with CH2Cl2:MeOH 95:5 (3 × 100 mL). The 
combined organic layers were washed with brine, dried over Na2SO4, and the solvent 





C NMR and MS data are in agreement with the literature.
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Synthesis of compound 2.12. Bromorhodamine 2.11 (200 mg, 0.378 mmol) was 
dissolved in a solvent mixture including toluene (2.7 mL), aqueous 2 M Na2CO3 (1.2 mL) 
and 4-(N-Boc-amino) phenylboronic acid (459 mg 1.938 mmol) in EtOH (1.2 mL). The 
mixture was deoxygenated under reduced pressure and flushed with Ar 3 times. 
Pd(PPh3)4 (48 mg, 11 mol%) was added, and the reaction mixture heated at 60ºC 
overnight. The solution was poured into H2O, and washed with 10% MeOH in CH2Cl2. 
The organic layers were washed with brine and dried over Na2SO4, filtered over a short 
plug of celite and the solvent removed under vacuum. The mixture was separated by flash 
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chromatography on SiO2 using CH2Cl2:MeOH 9:1 as the eluent to give a dark violet solid 
(109 mg, 45%). 
1
H NMR (CDCl3): 1.48 (9H, s, CH3),  1.92 (4H, m, CH2), 2.05 (4H, m, 
CH2), 2.65 (4H, t, J = 6.0 Hz, CH2), 2.98 (4H, d, J = 6.3 Hz, CH2), 3.47 (4H, t, J = 5.7 Hz, 
CH2), 3.51 (4H, t, J = 5.6 Hz, CH2), 6.83 (2H, s, CH), 6.95 (1H, s, NH), 7.29 (2H, s, J = 
8.2 Hz, CH,), 7.50 (2H, d, J = 8.6 Hz, CH), 7.56 (2H, d, J = 8.6 Hz, CH), 7.70 (2H, d, J = 
8.2 Hz, CH). 
13
C NMR (CDCl3): 19.9, 20.0, 20.8, 27.8, 28.5, 50.6, 51.1, 80.8, 105.5, 
112.9, 119.1, 123.8, 126.8, 126.9, 127.7, 130.1, 131.1, 134.1, 138.9, 142.2, 151.2, 152.3, 
153.0, 154.7. HRMS (ESI): m/z [M
+
] calculated for C42H44N3O3: 638.3377; observed: 
638.3378. 
Synthesis of compound 2.13. To a stirred solution of compound 2.12 (97 mg, 
0.151 mmol) in CH2Cl2 (3 mL) kept at 0 ºC, TFA (4.5 mL) was added dropwise.  The 
reaction was stirred for 2 h at 0 ºC, and neutralized with saturated aqueous NaHCO3 to 
pH 7. The organic layers were washed with H2O, then brine, dried over Na2SO4, and the 
solvent removed under vacuum. The mixture was separated by flash chromatography on 
SiO2 using a gradient solvent CH2Cl2:MeOH 95:5 to 90:10 as the eluent to afford a dark 
violet solid (yield: 72.4 mg, 89%). 
1
H NMR (CDCl3): 1.99 (4H, m, CH2), 2.12 (4H, m, 
CH2), 2.72 (4H, t, J = 6.0 Hz, CH2), 3.05 (4H, d, J = 6.3 Hz, CH2), 3.53 (4H, t, J = 5.7 Hz, 
CH2), 3.57 (4H, t, J = 5.7 Hz, CH2), 6.82 (2H, d, J = 8.5 Hz, CH), 6.92 (2H, s, CH), 7.33 
(2H, d, J = 8.3 Hz, CH), 7.74 (2H, d, J = 8.5 Hz, CH), 7.79 (2H, d, J = 8.3 Hz, CH). 
13
C 
NMR (CDCl3): 19.9, 20.0, 20.8, 27.8, 50.6, 51.1, 105.6, 113.0,  115.7, 123.7, 126.4, 
126.9, 128.1, 129.6, 130.1, 130.3, 142.8, 147.1, 151.2, 152.4, 155.0. HRMS (ESI): m/z 
[M
+
] calculated for C37H36N3O: 538.2853; observed: 538.2855. 
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Synthesis of compound 2.6. To a stirred solution of compound 2.13 (18.1 mg, 
0.0325 mmol) in anhydrous CH2Cl2 (8 mL) was added 1,1’-thiocarbonyldi-2(1H)-
pyridone (15.6 mg, 0.0672 mmol). The resulting mixture was stirred at rt for 18 h under 
Ar. The mixture was poured into CH2Cl2, washed with H2O, then brine, dried over 
Na2SO4, and the solvent removed under vacuum. The residue was purified by flash 
chromatography on SiO2 using CH2Cl2:MeOH 95:5 as the eluent to give a dark violet 
solid (13.8 mg, 71%). 
1
H NMR (CDCl3): 1.98 (4H, m, CH2), 2.11 (4H, m, CH2), 2.72 (4H, 
t, J = 5.9 Hz, CH2), 3.04 (1H, t, J = 6.3 Hz, CH2), 3.53 (4H, dd, J = 8.3 Hz, J = 6.2 Hz, 
CH2), 3.56 (4H, t, J = 5.6 Hz, CH2), 6.85 (2H, s, CH), 7.35 (2H, d, J = 8.5 Hz, CH), 7.41 
(2H, d, J = 8.3 Hz, CH), 7.70 (2H, d, J = 8.5 Hz, CH), 7.79 (2H, d, J = 8.3 Hz, CH). 
13
C 
NMR (CDCl3): 19.8, 20.0, 20.8, 27.8, 50.6, 51.1, 105.6, 112.8,  123.9, 126.5, 126.6, 
127.4, 128.4, 130.3, 131.2, 132.2, 134.9, 138.9, 141.1, 151.3, 152.3, 154.1. HRMS (ESI): 
m/z [M
+
] calculated for C38H34N3OS: 580.2417; observed: 580.2419.   
Synthesis of compound 2.15. Compound 2.15 was synthesized using a modified 
procedure reported previously.
59
 Under Ar, ytterbium(III) triflate (353 mg, 0.568 mmol) 
was added to solution of m-anisidine (1 g, 8.12 mmol) in HPLC grade acetone (40 mL). 
The reaction mixture was stirred at rt for 24 h. Acetone was removed in vacuo and the 
residue was dissolved in EtOAc, washed with H2O, brine and dried over Na2SO4 filtered 
and the solvent evaporated under vacuum. The mixture was then separated by flash 
column chromatography on SiO2 using Hexane:EtOAc 8:1 as the eluent to afford a pale 










Synthesis of compound 2.16. Compound 2.16 was synthesized using a modified 
procedure reported previously.
59
 Under Ar, compound 2.15 (5.55 g, 27.3 mmol), Cs2CO3 
(4.98 g, 15.29 mmol), and MeI (6.46 mL, 103.75 mmol) were added to anhydrous DMF 
(15 mL) and stirred at 90 
o
C for 3 h. DMF was removed in vacuo and the residue poured 
into H2O and washed with EtOAc (3 × 200 mL). The combined organic layers were 
washed with brine and dried over Na2SO4. The solvent was removed under reduced 





and MS data are in agreement with the literature.
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Synthesis of compound 2.17. Compound 2.17 was synthesized using a modified 
procedure reported previously.
59
 Under Ar, compound 2.16 (3.05 g, 14.04 mmol) was 
dissolved in glacial AcOH (8.19 mL). 48% aqueous HBr (10.05 mL, 88.84 mmol) was 
added and the mixture heated at reflux (118 
o
C) for 8 h. After cooling, the solution was 
neutralized to about pH 5-6 with 30% aq. NaOH. The aqueous phase was extracted with 
CH2Cl2 (3 × 150 mL) and the combined organic layers were washed with brine and dried 
over Na2SO4. The solvent was evaporated under reduced pressure. The mixture was then 
separated by flash column chromatography on SiO2 using Hexane:EtOAc 5:1 as the 




C NMR and MS data are 
in agreement with the literature.
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Synthesis of compound 2.19. In a 5 mL microwave tube, compound 2.17 (85 mg, 
0.737 mmol) and methyl 4-(4-formylphenyl)benzoate (50 mg, 0.208 mmol) were 
dissolved in 1 mL CH2Cl2. The solvent was purged using an N2 stream. The mixture was 
heated in a microwave reactor at 150 
o
C for 10 min. The mixture was dissolved in 
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CH2Cl2:MeOH (95:5, 1 mL) and tetrachloro-1,4-benzoquinone (76.75 mg, 0.312 mmol) 
was added to the solution, and vortexed at 1000 rpm for 15 min. The solvent was purged 
using an N2 stream. The mixture was separated via a short SiO2 plug using DCM:MeOH 
97:3 as the eluent to afford compound 2.19 as a purple solid (85.15 mg, 67%). 
1
H 
NMR(CDCl3) : 1.49 (12H, s), 1.80 (6H, s) 3.21 (6H, s), 3.97 (3H, s), 5.51(2H, s), 6.85 
(2H, s), 6.96 (2H, s), 7.52 (2H, d, J = 8.4 Hz) ,7.81 (2H, d, J = 8.6 Hz), 7.91 (2H, d, J = 
8.4 Hz), 8.18 (2H, d, J = 8.6 Hz). 
13
C NMR (CDCl3): 18.5, 29.44, 29.82, 33.51, 52.43, 
59.96, 96.20, 113.79, 122.00, 123.64, 125.59, 127.28, 127.76, 129.97, 130.23, 130.51, 





: 609.3112; observed 609.3125.  
Synthesis of compound 2.21. Compound 2.19 (36 mg, 0.059 mmol) was 
dissolved in MeOH:THF:H2O (5:3:1, 0.9 mL) and LiOH (7.07 mg, 0.295 mmol) was 
added. The reaction was stirred at rt overnight. After the reaction was complete (TLC), 
the residue was dissolved in CH2Cl2:H2O (1:1, 2 mL). 1 N HCl was slowly added until 
the mixture was at pH 5. The aqueous layer was extracted with CH2Cl2 (3 × 5 mL), and 
the combined organic layers were washed with brine and dried over Na2SO4. The solvent 
was evaporated under reduced pressure to afford compound 2.21 as a purple solid (27.43 
mg, 78%). 
1
H NMR(CD3OD) : 1.52 (12H, s), 1.83 (6H, s) 3.21 (6H, s), 5.69 (2H, s), 6.86 
(2H, s), 7.09 (2H, s), 7.65 (2H, d, J = 8.3 Hz) ,7.91 (2H, d, J = 8.3 Hz), 8.05 (2H, d, J = 
8.3 Hz), 8.16 (2H, d, J = 8.3 Hz). 
13
C NMR (CD3OD): 18.26, 29.16, 33.44, 61.26, 96.49, 
114.89, 123.14, 124.77, 126.63, 128.17, 128.75, 131.61, 133.38, 134.13, 143.18, 145.14, 
34 
 
154.82, 156.00, 159.86. HRMS (ESI): m/z [M
+
] calculated for C40H39N2O3
+
:595.2955; 
observed 595.2962.  
Synthesis of compound 2.7. Compound 2.21 (20 mg, 0.033 mmol) was dissolved 
in 0.2 mL of anhydrous THF. EDAC (7.72 mg, 0.04 mmol) was added in one portion 
followed by N-Hydroxy succinimide (NHS) (4.64 mg, 0.04 mmol). The reaction was 
stirred at rt for 24 h. Another 10 equiv of EDAC (64.32 mg, 0.336 mmol) were added and 
the reaction stirred at rt overnight. The reaction mixture was poured into 10 mL of 50 
mM pH 6 phosphate buffer and extracted with CH2Cl2 (3 × 15 mL). The combined 
organic layers were washed with brine and dried over Na2SO4, and the solvent evaporated 
under reduced pressure. The mixture was separated via a short SiO2 plug using 
CH2Cl2:MeCN 1:1, followed by gradient elution with CH2Cl2:MeOH 98:2 to 95:5 to 
afford the target compound 2.7 as a purple solid (19.55 mg, 84%). 
1
H NMR(CDCl3) : 
1.50 (12H, s), 1.81(6H, s), 1.95(4H, s), 3.23 (6H, s), 5.52 (2H, s), 6.86 (2H, s), 6.95 (2H, 
s), 8.28 (2H, d, J = 8.4 Hz) , 7.93 (2H, d, J = 8.2 Hz), 7.94 (2H, d, J = 8.6 Hz), 8.27 (2H, 
d, J = 8.3 Hz), 8.29 (2H, d, J = 8.6 Hz). 
13
C NMR (CDCl3): 18.54, 25.87, 29.46, 33.62, 
60.00, 96.25, 113.79, 121.92, 123.70, 124.86, 125.57, 127.71, 127.90, 130.34, 131.50, 





: 692.3119; observed 692.3129.  
Synthesis of compound 2.29. Under Ar, 2-bromo-4-methoxybenzaldehyde (1g, 
4.65 mmol) was added to a solution of anhydrous THF (2 mL) and MeOH (2 mL) at rt. 
NaBH4 (88mg, 2.33 mmol) was added in portions over 5 min. The reaction mixture was 
stirred at rt for 1.5 h and the solvent removed in vacuo. The residue was dissolved in 
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Et2O and partitioned using Et2O (10 mL), H2O (10 mL) and 2M HCl (1 mL). The organic 
layer was washed with water twice, dried over Na2SO4 and concentrated in vacuo to 




C NMR and MS data are in 
agreement with the literature.
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Synthesis of compound 2.25. Under Ar, compound 2.29 (900 mg, 4.15 mmol) 
was dissolved in anhydrous Et2O (13.5 mL). The solution was cooled using an ice bath 
and PBr3 (780 mmL, 8.29 mmol) was added. The reaction was allowed to warm to rt and 
stirred overnight. The resulting orange solution was very carefully poured into vigorously 
stirred ice H2O (20 mL) (CAUTION: HIGHLY EXOTHERMIC). Phases were separated, 
the combined organic layers were washed with saturated NaHCO3 (10 mL) and dried 
over Na2SO4. The solvent was removed in vacuo to afford compound 2.25  as a white 








Synthesis of compound 2.24. Compound 2.25 (1.04 g, 3.71 mmol) was added to 
a solution of KCN (483 mg, 7.42 mmol) in 20 mL EtOH. The reaction mixture was 
heated at reflux for 8 h. The solvent was removed in vacuo and the residue poured into 20 
mL H2O and extracted with EtOAc (3 × 30 mL). The organic layers were combined, 
washed with brine (20 mL), dried over Na2SO4 and concentrated in vacuo to afford 
compound 2.24 as a white solid (696 mg, 83%). 1H NMR, 13C NMR and MS data are in 
agreement with the literature.
63
  
Synthesis of compound 2.30. 40 wt. % methyl amine solution (6.61 mL, 76.42 
mmol) was added to cyclohexene oxide (5.15 mL, 50.95 mmol) dropwise at 0 
o
C over 1 h. 
36 
 
The solution was allowed to warm to rt, stirred overnight and refluxed at 100 
o
C for 3 h. 
After reaction completion (TLC) the solution was cooled to 0 
o
C and 30% aq. NaOH was 
added to attain a pH > 12. The reaction mixture was extracted with Et2O (3 × 200 mL) 
and dried over Na2SO4 and concentrated in vacuo to afford compound 2.26 as a colorless 








Synthesis of compound 2.39. Compound 2.39 was synthesized using a modified 
procedure described previously by Acker et al.
65
 Under Ar, 2-amino-4-methoxybenzoic 
acid (3 g, 17.95 mmol) was dissolved in 18 mL of anhydrous THF. Triphosgene (2.05 g, 
6.82 mmol) was weighed in a glove box and dissolved in 6 mL anhydrous THF. The 
triphosgene solution was withdrawn by syringe and added dropwise to the benzoic acid 
solution over 1 h. The reaction mixture was heated at reflux (76
 o
C) for 2 h. The solvent 
was removed under reduced pressure, and the residue poured into 30 mL of cold H2O. A 
white precipitate obtained was obtained by vacuum filtration, washed first with cold H2O 




C NMR and MS data are in 
agreement with the literature.
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Synthesis of compound 2.35. Under Ar, isatoic anhydride (3 g, 15.53 mmol), 
Cs2CO3 (2.83 g, 8.7 mmol) and MeI (3.67 mL, 59.02 mmol) were added to anhydrous 
DMF (11 mL) and stirred at 90 
o
C for 3 h. DMF was removed in vacuo, and the residue 
poured into 30 mL of cold H2O. The white precipitate formed was collected by vacuum 




C NMR and MS data are 





Synthesis of compound 2.43. m-anisidine (6g, 48.72 mmol) was dissolved in 180 
mL anhydrous C2H2Cl2 (DCE) followed by consecutive addition of ethyl 2-
cyclohexanonecarboxylate (9.35 mL, 58.46 mmol), NaBH(OAc)3 (15.49 g, 73.08 mmol) 
and AcOH (2.79 mL, 48.72 mmol). The reaction was stirred at rt overnight and 
monitored by TLC. After the reaction was complete, 180 mL of saturated NaHCO3 was 
poured into the mixture followed by stirring for 30 min. The reaction mixture was 
extracted with CH2Cl2 (3 × 150 mL) and the combined organic layers were dried over 
Na2SO4. The solvent was removed under reduced pressure and the residue was purified 
by flash column chromatography on SiO2 using Hexane:EtOAc 15:1 as the eluent to 
afford compound 2.43 as a colorless oil (9.3 g, 69%).
 1
H NMR(CDCl3) : 1.23(3H, t, J = 
7.1 Hz), 1.42-1.57 (3H, m) 1.64-1.75 (3H, m), 1.88-1.95 (1H, m), 1.97-2.07(1H, m), 
2.84-2.88 (1H, m), 3.75-3.77 (1H, m), 3.79 (3H, s) ,4.07-4.17 (2H, m), 4.4 (1H, s), 6.20 
(1H, t), 6.24-6.28 (2H, m), 7.08 (1H, t , J = 8.1 Hz). 
13
C NMR (CDCl3): 14.30, 23.03, 
23.34, 26.08, 29.08, 44.79, 51.62, 55.20, 60.43, 99.67, 102.52, 106.85, 130.09, 148.59, 
160.97, 174.09. HRMS (ESI): m/z [M + H
+
] calculated for C16H24NO3: 278.1751; 
observed 278.1743.  
Synthesis of compound 2.44. Under Ar, compound 2.43 (6 g, 21.63 mmol) was 
dissolved in 16 mL of anhydrous DMF followed by addition of Cs2CO3 (3.95 g, 12.11 
mmol) and MeI (5.12 mL, 82.2 mmol). The reaction mixture was heated at 90 
o
C and 
vigorously stirred for 3 h. After the reaction was complete, DMF was removed in vacuo 
and the residue poured into H2O (100 mL) and washed with EtOAc (3 × 150 mL). The 
combined organic layers were dried over Na2SO4 and the solvent was removed under 
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reduced pressure to obtain a light yellow oil (5.04 g, 80%). 
1
H NMR(CDCl3) : 1.20 (3H, t, 
J = 7.1 Hz), 1.35-1.45 (1H, m) 1.53-1.55 (1H, m), 1.64-1.68 (3H, m), 1.93-2.01(2H, m), 
2.39 (1H, q of d, J = 12.3, 3.7 Hz), 2.82 (3H, s), 3.08 (1H, m) ,3.75 (1H, d of t, J = 12.0, 
4.0 Hz), 3.78 (3H, s), 4.00-4.12 (2H, m), 6.27 (1H, m), 6.34 (1H, d, J = 8.3 Hz), 7.15 (1H, 
t, J = 8.2 Hz). 
13
C NMR (CDCl3): 14.28, 21.45, 26.69, 26.95, 28.83, 32.45, 42.09, 55.27, 
59.13, 60.20, 98.92, 100.67, 105.32, 129.95, 150.86, 160.97, 174.55. HRMS (ESI): m/z 
[M + H
+
] calculated for C17H25NO3: 292.1907; observed 292.1894.  
Synthesis of compound 2.40. A mixture of compound 2.44 (5.03 g, 17.26 mmol) 
and KOH (2.42 g, 43.14 mmol) in 15 mL MeOH were stirred at rt for 1h. An additional 5 
equiv of KOH (4.84 g) were added and stirring was continued overnight. After the 
reaction was complete, MeOH was removed under vacuum. The residue was poured into 
CH2Cl2 and diluted with H2O. The solution was acidified to pH 3 via slow addition of 1 
N HCl. The reaction mixture was extracted with CH2Cl2 (3 × 150 mL) and the combined 
organic layers were dried with Na2SO4. The solvent was removed in vacuo to afford a 
brown oil (crude yield: 4.5 g, 99%). 
1
H NMR(CDCl3) : 1.34-143 (2H, m), 1.34-1.56 (2H, 
m) 1.74-1.82 (4H, m), 2.31-2.35 (1H, m), 2.58(1H, t of d, J = 11.6, 3.8 Hz), 2.77 (3H, s), 
3.58 (1H, t of d, J = 11.4, 3.6 Hz), 3.80 (3H, s),  6.44 (1H, d of d of d , J = 8.2, 2.3, 0.6 
Hz ), 6.54 (1H, t, J = 2.3 Hz), 6.60 (1H, d of d, J = 5.3, 4.8 Hz), 7.15 (1H, t, J = 8.2 Hz). 
13
C NMR (CDCl3): 25.22, 25.57, 26.76, 29.43, 31.86, 46.12, 55.39, 63.07, 103.97, 105.29, 
110.12, 129.86, 151.29, 160.84, 177.78. HRMS (ESI): m/z [M + H
+
] calculated for 
C15H22NO3: 264.1594; observed 264.1582.  
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Synthesis of compound 2.34. A mixture of compound 2.40 (0.5 g, 1.9 mmol) and 
polyphosphoric acid (6.3 g) was heated to 120 
o
C for 20 min. The reaction was cooled to 
rt and the solution neutralized to pH 7-8 with 15% aq. NaOH. The reaction mixture was 
extracted with EtOAc and the combined organic layers were dried over Na2SO4 and the 
solvent removed in vacuo. The residue was purified by column chromatography on SiO2 
using Hexane:EtOAc 8:1 as the eluent to compound 2.34 as a yellow solid. (75.58 mg, 
16%). 
1
H NMR(CDCl3): 1.15-1.34 (3H, m), 1.42-1.51 (1H, m), 1.82-1.85 (1H, m), 1.89-
1.91(1H, m), 2.22-2.29 (1H, m), 2.34-2.38 (1H, m), 2.42-2.47 (1H, m), 2.90 (3H, s), 3.06 
(1H, d of d of d, J = 13.1, 11.3, 4.1 Hz ), 3.84 (3H, s), 6.25 (1H, d, J = 2.2 Hz), 6.36 (1H, 
d of d, J = 8.7, 2.3 Hz), 7.89 (1H, d, J = 8.7 Hz). 
13
C NMR (CDCl3): 24.76, 24.78, 24.87, 
31.62, 32.79, 50.36, 55.43, 62.12, 97.92, 104.37, 114.69, 130.34, 154.85, 165.49, 194.33. 
HRMS (ESI): m/z [M + H
+
] calculated for C15H21NO3: 246.1489; observed 246.1482 
Synthesis of compound 2.33. Under Ar, to a solution of compound 2.34 (1 g, 
4.08 mmol) in 12.5 mL of anhydrous Et2O was added LiAlH4 (464 mg, 12.23 mmol) 
portion-wise slowly. Once evolution of H2 ceased, 12.5 mL dry toluene was added and 
the reaction heated at reflux (120 
o
C) for 2h. The mixture was cooled to 0 
o
C and 
followed by dropwise consecutive additions of 0.5 mL of H2O, 0.5 mL of 15% NaOH 
and 1.5 mL of H2O. The resultant precipitate was removed by vacuum filtration, washed 
with 60 mL CH2Cl2. The filtrate was concentrated in vacuo to afford compound 2.33 as a 
light yellow solid (929 mg, 99%).
 1
H NMR (CDCl3): 1.07-1.21 (2H, m), 1.24-1.41 (2H, 
m), 1.51-1.61 (1H, m), 1.71-1.75 (1H, m), 1. 83-1.88 (2H, m), 2.26-2.30 (1H, m), 2.37-
2.45 (1H, m), 2.37-2.45 (1H, m), 2.52 (1H, d of d, J = 15.1, 4.2 Hz), 2.68 (1H, t of d, J = 
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10.6, 3.6 Hz), 2.9 (3H, s), 3.77 (3H, s), 6.17 (1H, d of d, J = 8.1, 2.4 Hz), 6.22 (1H, d, J = 
2.4 Hz), 6.81(1H, d, J = 8.0 Hz). 
13
C NMR (CDCl3): 25.30, 25.84, 32.44, 33.03, 34.84, 
35.99, 39.28, 55.34, 63.47, 99.44, 100.73, 116.63, 128.59, 148.47, 159.30. HRMS (ESI): 
m/z [M + H
+
] calculated for C15H22NO: 232.1696; observed 232.1684.  
Synthesis of compound 2.32. Under Ar, compound 2.33 (1 g, 4.32 mmol) was 
dissolved in glacial AcOH (2.5 mL), 48% aq. HBr (3.03 mL, 26.8 mmol) was added and 
the mixture heated at reflux (118 
o
C) overnight. After cooling, the solution was 
neutralized to pH 5-6 with 30% aq. NaOH. The aqueous phase was extracted with 
CH2Cl2 (3 × 100 mL) and the combined organic layers were washed with brine and dry 
over Na2SO4. The solvent was removed under reduced pressure to afford compound 2.32 
as a brown solid (938 mg, 100%). 
1
H NMR(CDCl3) : 1.06-1.20 (2H, m), 1.23-1.41 (2H, 
m), 1.50-1.60 (1H, m), 1.71-1.74 (1H, m), 1.83-1.87(2H, m), 2.25-2.29 (1H, m), 2.36-
2.42 (1H, m), 2.50 (1H, d of d, J = 15.1, 4.2 Hz), 2.68 (1H, t of d, , J = 10.6, 3.6 Hz), 2.87 
(3H, s), 6.06 (1H, d of d, J = 7.9, 2.4 Hz), 6.14 (1H, d, J = 2.3 Hz), 6.74 (1H, d, J = 7.8 
Hz). 
13
C NMR (CDCl3): 25.30, 25.83, 32.40, 33.02, 34.83, 35.87, 39.27, 63.38, 99.83, 
102.71, 116.35, 128.83, 148.64, 154.99. HRMS (ESI): m/z [M + H
+
] calculated for 
C14H20NO: 218.1539; observed 218.1522.  
Synthesis of compound 2.45. In a 2 mL microwave tube, compound 2.32 (108 
mg, 0.499 mmol) and methyl 4-(4-formylphenyl)benzoate (60 mg, 0.25 mmol) were 
dissolved in 1 mL CH2Cl2. The solvent was purged using an N2 stream. The reaction 
mixture was heated in microwave reactor at 150 
o
C for 10 min. The mixture was 
dissolved in CH2Cl2:MeOH (95:5, 0.5 mL) followed by addition of tetrachloro-1,4-
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benzoquinone (92.1 mg, 0.375 mmol) and vortexed at 1000 rpm for 15 min. The solvent 
was removed using an N2 stream. The mixture was separated via a short SiO2 plug using 
CH2Cl2:MeCN 1:1, followed by CH2Cl2:MeOH 97:3 as the eluent to give a dark purple 
solid (67.3 mg, 42%). 
1
H NMR(DMSO) : 1.11-1.47 (12H, m), 1.66-1.67 (2H, m), 1.77-
1.85 (4H, m), 2.34-2.47 (4H, m), 2.66 (2H, d, J = 14.2 Hz), 3.21 (6H, s), 3.91(3H, s), 
6.93 (2H, s), 6.99 (2H, s), 7.58-7.62 (2H, m), 7.99 (2H, d of d, J = 8.6, 2.1 Hz), 8.05 (2H, 
d of d, J = 8.5, 2.5 Hz), 8.11 (2H, d of d, J = 8.5, 1.1 Hz). 
13
C NMR (DMSO): 24.70, 
24.77, 30.67, 31.36, 33.47, 35.60, 38.16, 52.27, 63.81, 96.28, 112.75, 126.50, 127.17, 
127.35, 129.05, 129.97, 140.07, 143.49, 154.90, 156.48, 156.51, 165.99. HRMS (ESI): 
m/z [M
+
] calculated for C43H45N2O3
+
: 637.3425; observed 637.3381.  
Synthesis of compound 2.46. Compound 2.45 (67 mg, 0.105 mmol) was 
dissolved in MeOH:THF:H2O (5:3:1, 2.7 mL) and LiOH (12.58 mg, 0.525 mmol) was 
added. The reaction was stirred at rt overnight. After the reaction was complete, the 
residue was dissolved in CH2Cl2:H2O (1:1, 2 mL), and 1 N HCl was slowly added to 
reach pH 5. The aqueous layer was extracted with CH2Cl2 (3 × 5 mL), and the combined 
organic layers were dried over Na2SO4. The solvent was removed in vacuo to furnish a 
purple solid (59.42 mg, 91%). 
1
H NMR(CD3OD) : 1.14-1.48 (12H, m), 1.66-1.69 (3H, m), 
1.80-1.86 (3H, m), 2.34-2.48 (4H, m), 2.67 (2H, d, J = 13.6 Hz), 3.21 (6H, s), 6.9 (2H, s), 
7.0 (2H, s), 7.6 (2H, d, J = 7.6 Hz), 7.96 (2H, d, J = 8.3 Hz), 8.05 (2H, d, J = 8.2 Hz), 
8.10 (2H, d, J = 8.4 Hz). 
13
C NMR (CD3OD): 24.71, 24.77, 30.68, 31.36, 33.48, 35.61, 
38.17, 63.81, 96.27, 112.79, 126.52, 127.00, 127.31, 130.11, 131.86, 140.32, 143.00, 
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154.30, 154.92, 156.53, 167.09. HRMS (ESI): m/z [M
+
] calculated for C42H43N2O3
+
: 
623.3268; observed 623.3287.  
Synthesis of compound 2.8. Compound 2.46 (8 mg, 0.013 mmol) was dissolved 
in 0.2 mL of anhydrous THF. EDAC (3.69 mg, 0.019 mmol) was added in one portion 
followed by the addition of NHS (1.77 mg, 0.015 mmol). The reaction was stirred at rt 
for 4 h. Another 5 equiv EDAC (12.3 mg, 0.063 mmol) were added and the reaction 
stirred at rt overnight. The reaction mixture was poured into 5 mL of 50 mM pH6 
phosphate buffer, and extracted with CH2Cl2 (3 × 5 mL). The combined organic layers 
were washed with brine and dried over Na2SO4 and the solvent evaporated in vacuo. The 
mixture was separated via a short SiO2 plug using CH2Cl2:MeCN 1:1 then DCM:MeOH 
96:4 to afford the target compound 2.8 as a purple solid (7.68 mg, 83%). 
1
H 
NMR(CDCl3): 1.13-1.32 (8H, m), 1.36-1.42 (2H, m), 1.47-1.57(2H, m), 1.74 (2H, d, J = 
12.3 Hz), 1.84 (2H, d, J = 12.3 Hz), 1.92 (2H, d, J = 13.1 Hz), 2.42-2.49 (4H, m), 2.60 
(2H, d of d, J = 15.2, 2.6 Hz), 2.93 (4H, s), 3.12-3.18 (2H, m), 3.24 (6H, s), 6.82 (2H, s), 
6.94 (2H, s), 7.49 (2H, d, J = 8.2 Hz), 7.84 (2H, d, J = 8.5 Hz), 7.88 (2H, d, J = 8.3 Hz), 
8.26 (2H, d, J = 8.5 Hz). 
13
C NMR (CDCl3): 25.16, 25.25, 25.84, 29.76, 31.51, 32.04, 
34.63, 36.20, 38.85, 64.80, 96.96, 113.59, 124.70, 126.83, 126.85, 126.91, 127.66, 127.87, 
127.91, 127.95, 130.16, 130.26, 130.36, 131.46, 132.68, 141.10, 146.13, 154.62, 155.56, 
157.24, 157.26, 161.70, 169.39. HRMS (ESI): m/z [M
+
] calculated for C46H46N3O5
+
: 





Molecular simulations guided the design of geometrically rigid fluorophores. A 
series of well-defined rhodamine analogs (2.6, 2.7 and 2.8) have thus been synthesized to 
serve as the optical components of cationic drug-gentamicin conjugates. Inflexible Texas 
Red, 2.6, was synthesized in four steps in 13% overall yield.  A direct condensation of 
hydroxyl-quinoline and methyl 4-(4-formylphenyl)benzoate afforded the precursor to 
target 2.7. Several attempts were evaluated to prepare the key intermediate to rhodamine 
2.8. An alternative approach including reductive amination and intramolecular Friedel-
Crafts acylation was successful. The overall yield for 2.7 (6 steps) and 2.8 (9 steps) are 
17% and 3%, respectively. Rhodamine derivatives, 2.6, 2.7 and 2.8 in DPS/DMSO 
exhibited signs of aggregation, but in MeOH exhibited overall similar spectral properties 











2.7 Future Work 
 Continued systematic changes to fluorophore dimensions while keeping the rigid 
linker. 
 Synthesis of fluorophores with semi-flexible (glycol) and flexible (alkyl) linker. 
 
A series of gentamicin-fluorophore conjugates containing biaryl (inflexible), 
glycol (semiflexible) or alkyl (flexible) linkers will enable library generation and ensuing 
structure-activity relationship (SAR) studies to investigate if changing the fluorophore 
itself or linkers can help preserve fluorescence properties in cellular studies and 





CHAPTER 3      THE UTILITY OF RIGID FLUOROPHORE-GENTAMICIN 
CONJUGATES IN ZEBRAFISH AND KIDNEY CELL TRAFFICKING STUDIES 
3.1 Introduction 
AGs are essential for treating life-threatening bacterial sepsis, yet induce acute 
nephrotoxicity and permanent deafness. In order to have a better understanding of how 
AGs enter ear hair cells and kidney cells, GTTR 2.1 has been mainly used to study the 
mechanism of drug uptake. Recently, a candidate aminoglycoside transporter (sodium-
glucose transporter-2; SGLT2) was identified that might be associated with kidney 
cytotoxicity.
72
 Molecular simulations (Figure 2.4) show that GTTR has a flexible linker 
that promotes conjugate folding thereby reducing its cross sectional diameter to pass 
through non-selective cation channels. A series of rigid and extended rhodamine 
derivatives (2.6, 2.7 and 2.8) have been used to conjugate to gentamicin (2.3 and 2.4; 2.5 
is in progress). The conjugates were prepared at OHSU by Meiyan Jiang in Prof. 
Steyger’s group (Figure 3.1). These new analogs can serve as molecular rulers to 
determine the maximum dilated MET channel or transporter pore size, to better inform 
the prevention of cochlear hair cell uptake to preserve lifelong auditory function.   
 
3.2 Synthesis of gentamin conjugates 
Conjugates (2.1, 2.3 and 2.4) were prepared using similar reaction condition as 
shown in Figure 3.1. Conjugation of the activated fluorophore (2.2, 2.6 and 2.7) to 
gentamicin was carried out at pH 10 in aqueous media at rt (using a molar ratio of 
fluorophore:gentamicin 1:100 in order to ensure that only one molecule of the 
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fluorophore is conjugated to one molecule of gentamicin) with 60%, 25% and 10% yield, 
respectively. 
 




3.3 Cell Imaging Studies 
MDCT (Mouse Distal Convoluted Tubule Cell Line) cells and zebrafish were 
used to study cellular uptake with conjugates 2.3 and 2.4 to evaluate the maximum 
permeation/dilation diameter of aminoglycoside-permissive channels and aminoglycoside 
transporters in hair cells and kidney cells.  
3.3.1 MDCT cell  
MDCT cells were chosen as an in vitro model of strial cells due to their common 
ion regulatory functions. MDCT cells were incubated with 5 μg/ml of each conjugate or 
the free fluorophores. As shown in Figure 3.2, there is a strong bright cytoplasmic and 
intra-nuclear fluorescence of MDCT cells (A1). MDCT cellular uptake of gentamicin 
diminishes with the increase in the cross-sectional diameter of the fluorophore. 
(Fluorescence intensity: 2.1 > 2.3 > 2.4). This result suggests that larger diameter 
fluorophores may potentially prevent kidney cell gentamicin uptake. There is no uptake 
of free fluorophore as shown in B1, B2 and B3.  
 
Figure 3.2 Cellular uptake of MDCT cells. 
MDCT cells were incubated with 5 μg/ml conjugates. 2.1 (A1), 2.3 (A2) and 2.4 (A3); 
free fluorophores 2.2 (B1), 2.6 (B2) and 2.7 (B3) in PBS for 30 s, then fixation with 4% 





Zebrafish are used as an ideal model for drug-screening assays due to its small 
size, optical transparency and high proliferation.
73
 Also, they possess mechanosensitive 
hair cells on the surface of their body on the lateral line (sensory) system, sharing 
structural and molecular similarities with mammalian inner ear hair cells. They are also 
sensitive to aminoglycosides antibiotics.
74
 The mariner zebrafish mutants have defective 
myosin VIIa that is critical for mechanotransduction by hair cells, and display defects in 




As shown in Figure 3.3, zebrafish were treated with 1 µg/ml conjugates or free 
fluorophores for 10 min before fixation. Zebrafish neuromasts treated with 2.3 and 2.4 
had significantly reduced hair cell uptake of gentamicin as compared to neuromasts 
treated with 2.1 only (A1-C1). These results indicate that the molecular modification of 
fluorophores reduces conjugate permeation through the MET channel and could prevent 
hair cell cytotoxicity. Based on the cross-sectional diameter of 2.3 and 2.4, we can 
assume that the dilated MET channel pore size is approximately between 1.44 nm and 
1.56 nm. Hair cell uptake was reduced in mariner zebrafish neuromasts compare to wild-
type zebrafish. The myosin VIIa mutant zebrafish mariner with defective 
mechanotransduction is protected against hair cell damage caused by gentamicin (A1-F1). 




Figure 3.3 Cellular uptake with 1 µg/ml conjugates and free fluorophores by wild-type 
and mariner zebrafish.  
Neuromast hair cells can be identified by phalloidin-labeled (green) cuticular plates. 2.1 
uptake (red) by hair cells is preferentially localized within the cytoplasm. A1-A2: 
Neuromast hair cells of wild-type larva incubated with 2.1 for 10 min display robust 
fluorescence. B1-B2: Neuromast hair cells of wild-type larva incubated with 2.3 for 
10 min display less fluorescence intensity than 2.1. C1-C2: Neuromast hair cells of wild-
type larva incubated with 2.4 for 10 min display almost no fluorescence. D1-F2: 2.1, 2.3, 
2.4 uptake in the neuromast hair cells of mariner larva are much less than that in wild-
type larva. G1-I2: Neuromast hair cells of wild-type larva treated with the same dose of 
unconjugated 2.2, 2.6 or 2.7 for 10 min display negligible fluorescence. J1-L2: 
Neuromast hair cells of mariner larva treated with the same dose of unconjugated 2.2, 2.6 




3.4 Experimental Section 
Synthesis of Gentamicin-Texas Red conjugate, 2.1. An excess of gentamicin 
(Sigma, MO, USA) in 0.1 M potassium carbonate (pH 10) was mixed with TR-SE 2.2 
(Invitrogen, CA) to minimize the possibility of over-labeling individual gentamicin 
molecules with more than one TR molecule, and to preserve the polycationic nature of 
the conjugate. After conjugation, reversed phase chromatography, using C-18 columns 
(Grace Discovery Sciences, IL), was used to purify GTTR from unconjugated gentamicin, 
and potential contamination by unreacted TR. The purified GTTR conjugate was 
aliquoted, lyophilized, and stored desiccated in the dark at -20 
o
C until use. 
Synthesis of 2.6-gentamicin conjugate, 2.3. An excess of gentamicin (Sigma, 
MO, USA) in 0.1 M potassium carbonate (pH 8) was mixed with 2.6 (gentamicin: 2.6 = 
100:1). The conjugation mixture reacted at rt for 2 days. After conjugation, 
chromatography using alumina columns and acetonitrile was used to purify 2.3 from 
unconjugated gentamicin, and potential contamination by unreacted 2.6. The purified 2.3 
was aliquoted, lyophilized, and stored desiccated in the dark at -20 
o
C until use. 
Synthesis of 2.7-gentamicin conjugate, 2.4. An excess of gentamicin (Sigma, 
MO, USA) in 0.1 M potassium carbonate (pH 9) was mixed with 2.7 (gentamicin: 2.7 = 
100:1). The conjugation mixture was left to react at rt for 7 days. After conjugation, 
reverse phase chromatography, using C-18 columns (Grace Discovery Sciences, IL), was 
used to purify 2.4 from unconjugated gentamicin, and potential contamination by 
unreacted 2.7. The purification procedure is the same as GTTR purification. The purified 
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Gentamicin uptake by MDCT cells. MDCT cells plated on 8-well chambered 
coverslips were washed with cell medium twice, incubated with 5 μg/ml conjugates or 
free fluorophores in PBS for 30 s at rt to preclude endocytosis, then washed with PBS 
three times to remove conjugate from extracellular media prior to fixation with 4% 
paraformaldehyde containing 0.5% Triton X-100 for 30 min. The cellular distribution of 
conjugate fluorescence was examined using a Bio-Rad 1024 ES scanning laser system. 
For each individual set of images to be compared, the same confocal settings were used, 
with two acquisition images per well, two wells per experimental condition, and each 
experiment performed at least three times to confirm the consistency of experimental data. 
Gentamicin uptake by zebrafish. Zebrafish wild-type and mariner zebrafish 
larvae, 5 days after fertilization, were treated with conjugates or free fluorophores; 
(1µg/ml in standard E3 medium for 10 min prior to fixation in 4% formaldehyde for 1 h 
and 0.5% Triton X-100 for 30 min.) Larvae were then labeled with Alexa-488-conjugated 
phalloidin to confirm hair cell bundles by confocal microscopy.  
 
3.5 Conclusion 
Genetic inhibition of mechanotransduction reduces gentamicin-fluorophore 
conjugate uptake. Also, structural modifications of the fluorophore reduce or block 
gentamicin uptake in kidney and hair cells. The conjugates via their fixed diameters, 
when used as to measure the maximum dilated MET channel pore size, show that this 
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might be between 1.44 nm to 1.56 nm. However, this needs further validation, for 




 Synthesis of fluorophore-gentamicin conjugate 2.5   
 Use conjugate 2.5 to verify the dilated ion channel pore size and test if the 
structure of this fluorophore is effective in blocking cellular uptake. 





CHAPTER 4      SYNTHESIS OF A CISPLATIN-TEXAS RED CONJUGATE  
4.1 Introduction 
Cisplatin is one of the most powerful anticancer drugs used to treat a wide range 
of cancers. However, its unwanted side-effects such as ototoxicity and nephrotoxicity 
remain problematic at the dose required for clinical efficacy. There have been several 
studies to identify the biodistribution of cisplatin in cells and tissues using positron 
emission tomography, radiolabeled cisplatin and high-performance liquid 
chromatography (HPLC).
76-79
 Morphologically, these techniques have low anatomic 
resolution, and cannot provide the cellular distribution of cisplatin in heterogeneous 
cellular tissues, like the cochlea in the inner ear. In order to investigate the cellular uptake 
and intracellular distribution of cisplatin, the use of fluorogenic probes offers an 
alternative method to these techniques. A fluorescein-cisplatin conjugate has been 
reported to enter cells via endocytosis.
80
 Recently, a rhodamine-cisplatin has been 
reported to enter sensory hair cell of the zebrafish neuromast via their apical membranes, 
potentially via the MET channel or calmodulin-dependent endocytosis.
35
 Several 
fluorophore-cisplatin conjugates, including fluorescein, cyanine, coumarin and 
dinitrophenyl, have also been studied (Figure 4.1).
81
 Results reveal that the reactivity of 
the cisplatin conjugate towards a guanine base is determined to a large extent by the 
charge properties of the fluorophore: cationic > neutral > anionic.  
Thus, it is proposed that the conjugation of anionic dyes such as fluorescein 
diminishes or neutralizes cisplatin’s cationic properties and thus change its bioactivity, as 
observed for fluorescein-conjugated aminoglycosides.
36
 In order to preserve the drug 
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cationic properties, it was envisioned that tagging cisplatin with a rhodamine type 






Figure 4.1 Fluorophores have been conjugated with cisplatin and its structure 
 
Therefore, a method was described here to conjugate a cationic commercially-
available fluorophore, TR-SE 2.2 to cisplatin (4.1, Figure 4.1) and following systemic 
injection, will allow to determine localization of cisplatin uptake mechanism within 
cochlear. A fluorescein-cisplatin conjugate (4.2) was also synthesized and used as a 
control to study the fluorophore property influence on cellular uptake. A better 
understanding of the biodistribution of cisplatin, and uptake mechanisms, will facilitate 
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the design of new platinum-based pharmacotherapies to diminish or ameliorate the 
devastating side effects of cisplatin therapy.  
 
 
Figure 4.2 Isomers of Cisplatin-Texas Red conjugate, 4.1 and fluorescein conjugate, 4.2  
 
4.2 Synthetic strategies of cisplatin conjugates 
4.2.1 Synthesis of cisplatin-fluorescein conjugate, 4.2 
Platinum complex 4.5 was considered appropriate as a cisplatin analogue as it 
contains a short linker for conjugation and has biological properties similar to cisplatin.  
Complex 4.3 is synthesized in three steps as described previously by Benoist et al.
83
 The 
Boc-protected ligand 4.3 possessing free amino groups can, upon chelation with Pt(II), 
afford complex 4.4 in 75% yield. The deprotected platinum complex 4.5 is obtained 
quantitatively by acid hydrolysis of 4.4.
84
 The overall yield for the platinum complex 4.5 




Scheme 4.1 Synthesis of platinum complex 4.5 
 
The synthesis of control fluorescein-cisplatin conjugate (DDP-Fl) was carried out 
as shown in scheme 4.2. using a known protocol reported by Molenaar et al.
84
 
Commercially available fluorophore, 5(6)-carboxyfluorescein diacetate N-succinimidyl 
ester (4.6, CFDA-SE), is conjugated to deprotected platinum complex 4.5 in anhydrous 
DMF to afford 4.2 in 23% yield. 
 
Scheme 4.2 Synthesis of DDP-Fl, 4.2 
 
The reversed-phase HPLC analysis of both CFDA-SE 4.6 and the conjugate 4.2 
showed only one major peak, without separation. The purity of the conjugate was 





Figure 4.3 HPLC trace of compound 4.6 (isomer mixture).  
The injected volume: 5 L. Flow rate 0.2 mL/min; using a H2O:MeCN gradient 70:30 to 
95:5 in 25 min; wavelength detection 235 nm. 
 
 
Figure 4.4 HPLC trace of compound 4.2(isomer mixture).  
The injected volume: 5 L. Flow rate 0.2 mL/min; using a H2O:MeCN gradient 70:30 to 
95:5 in 25 min; wavelength detection 235 nm. 
 
4.2.2 Synthesis of cisplatin-Texas Red conjugste, 4.1 
The target DDP-TR 4.1 was synthesized as shown in scheme 4.3 in 48% overall 
yield. Conjugation was performed by reacting commercially available fluorophore, TR-
SE 1.1, with deprotected platinum complex 4.5 under basic conditions in 88% yield.  
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Pt NMR and LC/MS. The 
195
Pt 
NMR spectrum of conjugate 4.1 exhibits a chemical shift at -2265.40 ppm while the 
resonance of its parent Pt complex 4.5 is at -2367.05 ppm. 
 
 
Scheme 4.3 Synthesis of DDP-TR, 4.1 
 
Reversed-phase HPLC analysis shows that the commercial TR-SE 2.2 is actually 
a mixture containing two isomers (2.2a and 2.2b, Figure 4.5) in a 2:1 ratio (Figure 4.6). 
After conjugation of 2.2 to platinum complex 4.5, as expected a more hydrophilic 
molecule was obtained and the isomer ratio was unchanged (Figure 4.7). The purity of 
conjugate 4.1 (also a 2:1 mixture of isomers) was calculated as 97% by reversed phase 
HPLC. Table 4.1 shows the retention time and composition of both isomeric mixtures. In 
addition, the HR ESI positive mode MS spectrum was used to confirm the identity of 




Figure 4.5 Texas Red succinimidyl ester isomers 
 
 
Figure 4.6 HPLC trace of compound 2.2 (isomer mixture).  
The injected volume is 5 L. Flow rate 0.2 mL/min; using a H2O:MeCN gradient 95:5 to 
5:95 in 25 min; wavelength detection: 590 nm. 
 
 
Figure 4.7 HPLC trace of compound 4.1 (isomer mixture).  
The injected volume is 5 L. Flow rate 0.2 mL/min; using a H2O:MeCN gradient 95:5 to 
















































Table 4.1 Retention times and peak areas for each isomer. 










Peak 1 16.39 19.00 66.88 66.85 
Peak 2 17.92 20.98 33.12 33.15 
 
4.3 Spectral properties 
Spectroscopic characterization of the cisplatin-Texas Red conjugate 4.1 
In order to determine the newly conjugate 4.1 has the similar spectral properties 
as the parent probe TR-SE (2.2), the absorbance and fluorescence spectra of 1.25 M 
solution of 4.1 and 2.2 were evaluated in MeOH. 
Compound 4.1 revealed that the conjugate has similar maximum absorbance 
intensity as compared to the parent fluorophore, 2.2 (Figure 4.8). As shown in Figure 4.9, 
the fluorescence excitation maximum was slightly red-shifted by 5 nm in compound 4.1, 
otherwise negligible changes in emission spectra were observed compared to 2.2. 




Figure 4.8 Absorption spectra of 1.25M of 4.1 and 2.2 in MeOH. 
 
Figure 4.9 Excitation/Emission fluorescence spectra of 1.25 M of 4.1 and 2.2 in MeOH. 
 
4.4 Cellular studies 
In order to test the hypothesis that anionic fluorescein will diminish cisplatin’s 
cationic properties and change its bioactivity, both DDP-Fl (4.2) and DDP-TR (4.1) were 
used in MDCK (Madin-Darby Canine Kidney) cells for this study. In addition, zebrafish 





























































Cellular uptake by MDCK cells with DDP-Fl (4.2) and DDP-TR (4.1) 
Cells were incubated with 10 g/ml of DDP-Fl or DDP-TR for 30 s at rt to 
preclude endocytosis, then fixed with formaldehyde plus Triton X-100 for 40 min and 
imaged with similar laser power settings. Cellular uptake of DDP-TR had stronger 
fluorescent intensity than cells treated with DDP-Fl. This suggests that anionic property 
of fluorescein may potentially change the bioactivity of cisplatin and renders no cellular 
uptake. (Figure 4.10) 
 
 
Figure 4.10 Comparison of DDP-Fl (A) and DDP-TR (B) uptake by MDCK cells.  
MDCK cells were treated with 10 g/ml of conjugates for 30 s at 20°C to preclude 
endocytosis, fixed with formaldehyde plus Triton X-100 for 40 min. The scale bar is 10 
microns. 
 
DDP-TR toxicity in zebrafish neuromast hair cells 
To verify that DDP-TR retains the cytotoxic properties of cisplatin, the relative 
toxicity of cisplatin and DDP-TR were compared using zebrafish neuromast hair cells. 
Larvae were treated with a dose range of cisplatin, DDP-TR, or unconjugated Texas Red 
for 4 h and allowed to recover for 3 h. 
Alexa-488-conjugated phalloidin labeling of the hair bundle and cuticular plate 





 yet the loss of the hair bundle or cuticular plate is an ototoxic 
event. After treatment with DDP-TR (10-200 mg/mL) for 4 h, plus 3 h of recovery, the 
number of surviving hair cells decreased with increasing dose (Figure 4.11A-C, E). 
Treatment with unconjugated Texas Red revealed no fluorescence in hair cells suggesting 
that the forced uptake of Texas Red, via conjugation to cisplatin, was responsible for the 
enhanced toxicity of DDP-TR. (Figure 4.11D) To quantify and normalize this decrease, 
untreated controls provided a baseline to determine the ratio of surviving hair cells in 
zebrafish neuromasts. Both cisplatin and DDP-TR decreased hair cell numbers in a dose-
dependent manner (Figure 4.11E).   
     
Figure 4.11 Cytoxicity in zebrafish neuromast hair cells with a range of dose. 
(A-C) To verify the cytotoxicity of DDP-TR, 4.1 a zebrafish was treated with various 
concentrations of conjugate (50-200 mg/mL) for 4 h, plus 3 h of recovery. Upon 
increasing the dose of conjugate, the number of hair cells decreased. (D) Treatment with 
unconjugated Texas Red showed no fluorescence within neuromasts. (E) Quantifying the 
relative surviving hair cells of zebrafish with cisplatin and conjugate treatment: the 




4.5 Experimental section 
Material and Methods 







Pt-NMR were acquired on an ARX-400 Avance Bruker 
spectrometer. Chemical shifts (δ) are given in ppm relative to TMS. For 
195
Pt-NMR, 
K2PtCl4 was used as external standard. Mass spectra was conducted at PSU Bioanalytical 
Mass Spectrometry Facility on a ThermoElectron LTQ-Orbitrap Discovery high 
resolution mass spectrometer coupled to an Accela HPLC system. The reversed phase 
HPLC consists of a 1525 binary delivery system, and a 2996 Photodiode array detector 
(Waters). A Supelco
TM
 C-18 (25 cm × 2.1 mm, 5 m) column was used for the separation. 
Fluorescence measurements were carried out on a Cary Eclipse
TM
 fluorescence 
spectrophotometer (Agilent Technologies), and absorption measurements were performed 
on a Cary Eclipse
TM
 50 Bio UV-Vis spectrophotometer.  
Synthesis of N3-(tert-Butoxycarbonyl)-1,2,3-propanetriamine, 4.3. Compound 
4.3 was synthesized from 3-amino-1,2-propanediol in three steps as reported by Benoist 




Synthesis of N-(tert-Butoxycarbonyl)-1-aminomethyl-1,2 ethylenediamine) 
dichloroplatinum(II), 4.4. Compound 4.4 was synthesized using a modified procedure 
reported previously by Molenaar et al. Under Ar system, K2PtCl4 (1.1 g, 2.64 mmol) was 
dissolved in 50 mL of DI water. The Boc-protected diamine 4.3 (0.5 g, 2.64 mmol) was 
dissolved in 10 mL of DI water and added to the K2PtCl4 solution. The reaction mixture 
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was stirred at rt for 24 h, and a pale yellow solid was formed. The solid was filtered, 
washed with H2O (5 × 50 mL), and dried under vacuum (yield: 0.9 g, 75%). NMR 
spectroscopic and MS data are in agreement with the literature.
84
 
Synthesis of (1-aminomethyl-1,2-ethylenediamine)dichloroplatinum(II) 
hydrochloride, 4.5.  Compound 4.4 (0.518 g, 1.137 mmol) was suspended in 50 mL of 
0.1M HCl, followed by the addition of 2.5 mL of 1.0 M HCl. The reaction mixture was 
heated at 50 
o
C for 24 h. More 1 M HCl (0.5 mL) was added and the reaction mixture 
was kept at 50 
o
C for another 24 h. The reaction was cooled down to rt and the aqueous 
solution was filtered through a 22 µm syringe filter to remove white precipitates. The 
filtrate was evaporated under vacuum to afford a yellow solid (441 mg, 99%). NMR 
spectroscopic and MS data are in agreement with the literature.
84
  
Synthesis of DDP-Fl, 4.2. Compound 4.2 was synthesized using a procedure 
reported by Molenaar et al in 23% yield. NMR spectroscopic and MS data are in 
agreement with published values.
84
 
Synthesis of DDP-TR, 4.1. Platinum complex 4.5 (10.55 mg, 26.93 mol) was 
dissolved in 1.2 mL of anhydrous DMF and sonicated for 10 min. Et3N (10.24 µL, 73.44 
mol) was added in one portion and the mixture was sonicated for another 5 min, 
resulting in a clear pale yellow solution; if necessary, DI water was added in increments 
of 20 L and sonicated until completely dissolved. TR-SE 2.2 (20 mg, 24.48 mol; 
Invitrogen CA) was added, and the reaction mixture stirred at rt for 1 h, prior to 
evaporation under vacuum to afford a purple precipitate. The residue was centrifuged and 
washed with cold H2O (2 × 10 mL) and Et2O (3 × 10 mL) until the supernatant became 
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almost clear, and dried under vacuum to afford a purple solid (yield: 88%, 22.8 mg). 
HRMS (ESI): m/z [M + H
+
] calculated for C41H51Cl2N6O7PtS2: 1056.2282; observed 
1056.2354. Moreover, the HPLC-MS analysis confirms that the first peak from the 
conjugate isomers of 4.1 appears at 17.67 min with m/z of 1056.2322 for [M + H]
+
, and 
the second peak appears at 19.15 min with m/z of 1056.2260 for [M + H]
+
.    
HPLC Analysis 
HPLC analysis of Compounds 4.1 and 2.2. The injected volume of 4.1 and 2.2 
was 5 L. The mobile phase consisted of H2O:MeCN with a gradient elution from 95:5 to 
5:95 in 25 min, with a flow rate of 0.2 mL/min. The UV/Vis scan range was 200-700 nm. 
The detection wavelength was set at 590 nm. 
HPLC analysis of Compounds 4.2 and 4.6. The injected volume of 4.2 and 4.6 
was 5 L. The mobile phase consisted of H2O:MeCN with a gradient elution from 70:30 
to 95:5 in 25 min, with a flow rate of 0.2 mL/min. The detection wavelength was set at 
235 nm. 
Fluorescence Spectroscopic Evaluation 
Fluorescence Spectra of Compounds 4.1 and 2.2. Stock solutions of 4.1 and 2.2 
were prepared in MeOH. Fluorescence spectra were recorded at excitation/emission 
wavelengths of 585 nm/600 nm (compound 4.1) and 580 nm/600 nm (compound 2.2) 
with the bandwidths set at 5 nm. 
Cellular studies 
MDCK cells. MDCK cells were cultured in antibiotic and phenol red-free 
Dulbecco’s minimal essential medium (MEM, Invitrogen, Ca) with 10% fetal bovine 
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serum at 37°C with 5% CO2, 95% air. Cells were seeded into 8-well coverglass chambers 
(ISC BioExpress) at 3000 cells/well and grown for 5 days, when they had become 
subconfluent, cuboidal, and had time to develop tight junctions. Cells were washed three 
times with PBS (with 1.25 mM calcium) and treated with 10 g/ml of DDP-Fl or DDP-
TR for 30 s at 20°C to preclude endocytosis, fixed with formaldehyde plus Triton X-100 
for 40 min and then imaged with approximately similar laser power settings. 
Zebrafish. Wildtype zebrafish larvae, 5 days after fertilization, were treated with 
a dose range of DDP-TR or cisplatin (10 to 400 mg/ml in standard E3 medium) for 4 h 
and recovered for 3 h prior to fixation in 4% formaldehyde containing 0.5% Triton X-100. 
Larvae were then labeled Alexa-488-conjugated phalloidin to determine the number of 
surviving hair cell bundles.   
 
4.6 Conclusion 
Platinum complex 4.5 with a short linker for conjugation was synthesized in 5 
steps with 53 % yield. DDP-TR, 4.1 was successfully synthesized using platinum 
complex 4.5 conjugated with commercially available TR-SE (2.2) with an unchanged 
isomer ratio in 97% purity. Spectroscopic evaluation showed that the conjugation of 
cisplatin preserved the spectral properties of Texas Red, 2.2.  
Cellular studies showed that the anionic properties of fluorescin neutralize 
positive charge of cisplatin and change its bioactivity: there is no cellular uptake of DDP-
Fl by MDCK cell as comparison with DDP-TR, 4.1. Cisplatin is a relatively small 
molecule, so conjugation could alter the kinetics of uptake as well as cytotoxicity.  In 
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vitro studies showed that the new DDP-TR has similar but reduced cytotoxicity to hair 
cells as compared to unconjugated cisplatin, and in a dose-dependent manner.  
 
4.7 Future Work 
 Conjugation of cisplatin to the series of rhodamine analogs to serve the same 






CHAPTER 5      SYNTHESIS OF A TETRAAMINO PLATINUM-TEXAS RED 
CONJUGATE 
5.1 Introduction 
Carboplatin (Figure 5.1) is an analog of cisplatin and is widely used but for fewer 
types of cancers compared to cisplatin. These include ovarian, lung, and head and neck 
cancers.
25
 Carboplatin is less toxic as compared to cisplatin due to replacing cisplatin’s 
chloride leaving groups with a cyclobutane-1,1-dicarboxylato ligand.
86
 This increases 
stability and inhibits exchange with aqua ligands leading to the more bioactive form that 
induces cytotoxicity in the cochlea and kidney.
87
 Even though carboplatin is less ototoxic 
and nephrotoxic compared to cisplatin, the cytotoxicity and these unwanted side-effects 




Figure 5.1 Carboplatin 
 
A common structural feature shared by cisplatin and carboplatin is the diamine 
groups. These drugs can induce cytotoxicity through molecular interactions via their 
amino groups. It is hypothesized that proteins specifically bind to cisplatin and 
carboplatin at the two amines, and that the protein-drug interactions could induce cell 
death associated with toxicity to the cochlea and kidney. The analogous amine platinum 
complex (5.1, Figure 5.2) has been previously synthesized and used to identify cisplatin-





Therefore, in order to identify the biodistribution of platinum binding proteins in vivo in 
heterogeneous cellular composition in kidney and cochlea, it is proposed to synthesize 
the tetra-amino platinum Texas Red conjugate as shown in Scheme 5.1. 
 
5.2 Synthesis of a tetra-amino platinum complex and its Texas Red Conjugate  
 
Figure 5.2 Amino platinum complex 5.1 and its proposed Texas Red conjugate 5.2 
 
Platinum complex 5.1 was chosen as an analog of cisplatin and carboplatin 
because it contains a free amine terminated short linker to allow conjugation to the 
fluorophore.  It is expected that the two free amine groups will bind to proteins, which 
will allow one to determine if this structural feature is responsible for the lower 
cytotoxicity observed for carboplatin. 
The corresponding platinum complex, 4.5 and platinum complex 5.1, bearing a 
free amino group for further conjugation to other biomolecules, were synthesized as 
shown in scheme 5.1. Complex 5.1, was synthesized in 52% overall yield following a 
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modified procedure by Hall et al.
90
 The Pt complex 5.1 was obtained in 98% yield from 
4.5, via the formation of the di-aquo complex 5.3, followed by ligand exchange with 






Pt NMR and ESI/MS. The synthesis of conjugate 5.2 is currently underway, 
which will be performed by conjugation of 5.1 to TR-SE 2.2 under basic condition in 
anhydrous DMF or by ligand exchange following the same procedure as the one used to 
obtain compound 5.1.  
 
Scheme 5.1 Proposed synthetic scheme of 5.2 
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5.3 Conclusion and future work 
The tetra-amino platinum complex 5.1 has been synthesized and used to identify 
cispaltin-binding proteins. Effort is underway to synthesize a fluorescent tetra-amino 
platinum conjugate, 5.2. It will be used to study the biodistribution in vivo of the tetra-
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 APPENDIX A: 1H NMR, 13C NMR AND MS SPECTRA FOR SELECTED 
COMPOUNDS FROM CHAPTER 1 
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H NMR of compound 2.12 
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C NMR of compound 2.13 
 
 
























C NMR of compound 2.19 
 
 

























C NMR of compound 2.7 
 
 










































MS of compound 2.40 
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C NMR of compound 2.34 
 
 

























C NMR of compound 2.32 
 
 















MS of compound 2.45 
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C NMR of compound 2.46 
 
 



















 APPENDIX B: 1H NMR, 13C NMR, 195 Pt AND MS SPECTRA FOR 
SELECTED COMPOUNDS FROM CHAPTER 4 
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H NMR of compound 4.5 
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H NMR of compound 4.1 
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Pt NMR of compound 4.1 
 
 




MS of compound 4.2 
